Sorry for your loss Patriot. I have worried about cases like your aunt that would be misdiagnosed and ultimately mistreated because all common sense has gone out the window. Both drugs are contraindicated in someone with certain cardiac conditions. I pray you and your family peace. I lost a sister-in-law from an quinolone antibiotic she should not have been prescribed. Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease Plaquenil Hydroxychloroquine prolongs the QT interval. Use hydroxychloroquine with caution in patients with cardiac disease or other conditions that may increase the risk of QT prolongation including cardiac arrhythmias, congenital long QT syndrome, heart failure, bradycardia, myocardial infarction, hypertension, coronary artery disease, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte imbalances. Females, geriatric patients, patients with diabetes, thyroid disease, malnutrition, liver impairment, or those who drink alcohol to excess may also be at increased risk for QT prolongation. Chronic toxicity should be considered when conduction disorders (bundle-branch block, AV block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of hydroxychloroquine may prevent life-threatening cardiac complications. https://www.pdr.net/drug-summary/Plaquenil-hydroxychloroquine-sulfate-1911 Azithromycin Data from a cohort study has associated azithromycin with an increased risk of cardiovascular death. The study included persons receiving prescriptions for azithromycin (n=347,795), amoxicillin (n=1,348,672), ciprofloxacin (n=264,626), levofloxacin (n=193,906), and matched persons receiving no antibiotics (n=1,391,180). Analysis of the data found those persons receiving a 5-day course of azithromycin had significantly greater risk of cardiovascular death than persons not treated with antibiotics (HR: 2.88; 95% CI: 1.79—4.63; P<0.001), persons treated with 5 days of amoxicillin (HR: 2.49; 95% CI: 1.38—4.50; P=0.002), and persons in the first 5 days of ciprofloxacin therapy (HR: 3.49; 95% CI: 1.32—9.26; P=0.01); mortality rate did not differ from levofloxacin. In addition, cases of torsade de pointes (TdP) have been noted during azithromycin post-marketing surveillance. Based on these data, the FDA has issued a Drug Safety Communication to alert health care professionals that azithromycin is associated with QT prolongation, imparting a risk of developing fatal cardiac arrhythmias such as TdP. Although this Drug Safety Communication focused on azithromycin, the FDA reminds prescribers that QT prolongation has also been associated with other macrolide and non-macrolide antibiotics, including fluoroquinolones. Health care providers should assess the risks and benefits of prescribing these drugs to at-risk groups, including patients with known prolongation of the QT interval or a history of TdP. Use azithromycin with caution in patients with cardiac disease or other conditions that may increase the risk of QT prolongation including cardiac arrhythmias, congenital long QT syndrome, heart failure, bradycardia, myocardial infarction, hypertension, coronary artery disease, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte imbalances. Females, elderly patients, patients with diabetes mellitus, thyroid disease, malnutrition, alcoholism, or hepatic impairment may also be at increased risk for QT prolongation.  https://www.pdr.net/drug-summary/Azithromycin-azithromycin-24249